Pharnext Logo

Pharnext

Develops therapies for neurodegenerative diseases by combining existing drugs.

ALPHA | Euronext Growth

Overview

Corporate Details

ISIN(s):
FR0011191287 (+4 more)
LEI:
969500KJGF9ZUYXSMJ27
Country:
France
Address:
9 RUE DES FILLES SAINT-THOMAS, 75002 PARIS

Description

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-08-27 13:00
Ouverture d'une procédure de liquidation judiciaire
French 194.1 KB
2024-08-01 18:00
Ajustement de la valeur nominale
French 189.9 KB
2024-07-18 18:00
Point concernant l'accord de financement en obligations convertibles accordé pa…
French 194.2 KB
2024-07-15 18:00
Demande d'ouverture d'une procédure de liquidation judiciaire
French 193.2 KB
2024-07-10 08:00
Pharnext fait un point sur sa situation financière
French 191.6 KB
2024-07-04 20:00
Pharnext annonce la résiliation du contrat de financement accordé par Néovacs
French 232.3 KB
2024-07-03 08:00
Pharnext fait un point sur les conséquences de sa situation stratégique et fina…
French 208.2 KB
2024-07-01 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 185.7 KB
2024-06-28 08:00
Pharnext fait un point d'étape sur les dernières avancées majeures d'un point d…
French 209.3 KB
2024-06-18 18:30
Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 jui…
French 194.9 KB
2024-06-05 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 181.3 KB
2024-05-29 18:00
Ajustement de la valeur nominale
French 190.9 KB
2024-05-07 19:10
Ajustement de la valeur nominale
French 190.6 KB
2024-05-06 18:00
Pharnext convoque ses actionnaires en assemblée générale le 10 juin 2024
French 194.7 KB
2024-05-02 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 195.4 KB

Automate Your Workflow. Get a real-time feed of all Pharnext filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharnext

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharnext via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Cardiol Therapeutics Inc. Logo
Clinical-stage company developing anti-inflammatory and anti-fibrotic heart therapies.
United States of America
CRDL
CAREGEN CO.,LTD. Logo
Develops biomimetic peptides and growth factors for aesthetic and medical solutions.
South Korea
214370
Caribou Biosciences, Inc. Logo
Clinical-stage biopharma developing genome-edited allogeneic cell therapies.
United States of America
CRBU
Carisma Therapeutics Inc. Logo
A clinical-stage biotech developing engineered macrophage-based therapeutics for cancer.
United States of America
CARM
Carna Biosciences, Inc. Logo
Clinical-stage biopharma developing small molecule kinase inhibitors.
Japan
4572
Cartesian Therapeutics, Inc. Logo
A clinical-stage company developing mRNA-engineered cell therapies for autoimmune diseases.
United States of America
RNAC
CASI Pharmaceuticals, Inc. Logo
Biopharmaceutical firm developing therapeutics for organ transplant and autoimmune diseases.
United States of America
CASI
CATALYST PHARMACEUTICALS, INC. Logo
Biopharmaceutical company commercializing drugs for rare neurological and autoimmune diseases.
United States of America
CPRX
cbdMD, Inc. Logo
Producer and distributor of health and wellness CBD products from U.S.-grown hemp.
United States of America
YCBD
CDT Equity Inc. Logo
A clinical-stage biopharmaceutical firm advancing assets for unmet medical needs.
United States of America
CDT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.